Hologic N.V.

We Are Hologic

As a leading global healthcare and diagnostics company, we strive to make advances toward greater certainty for our customers by providing them with cutting-edge technology that makes a real difference. We move to narrow the gap between doubt and confidence and work to achieve both incremental and transformational progress to improve patients’ lives.

We are passionate and resolute in our purpose; we call it The Science of Sure. This ethos is extended throughout our core offerings: Breast & Skeletal Health, Diagnostic, and GYN Surgical Solutions. We believe it is our responsibility to offer our customers ever-greater certainty – what we call progressive certainty – by pushing the boundaries of science.

We act with integrity. We innovate with determination. We are Hologic.

Events

Events not available

News

IMAGING Management

Hologic to Showcase Award-Winning Breast Screening and Interventional Solutions at RSNA

2016 27 Nov

--New products spotlight Hologic's leading tomosynthesis technology, including the world's first dedicated prone biopsy system with 2D or 3D™ imaging--Hologic, Inc. (Nasdaq: HOLX) will highlight its portfolio of innovative, award-winning breast cancer screening and interventional products, including the new Affirm™ prone breast biopsy system, at the... Read more

IMAGING Management

First Reviews of New Hologic Affirm™ Prone Biopsy System are Very Positive

2016 06 Nov

Breast tomosynthesis exams, Hologic calls the exams 3D MAMMOGRAPHY, have shown to be an advance over digital mammography, with higher cancer detection rates and fewer patient recalls for additional testing   The new Affirm prone system, which was installed for the first time in Europe earlier this year, is widely considered one the most significant... Read more

IMAGING Management

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2016

2016 03 Nov

- GAAP Diluted EPS of $0.33 Increases 266.7%, Non-GAAP Diluted EPS of $0.52 Increases 20.9% -- Revenue of $726.8 Million Grows 3.4%, 3.8% in Constant Currency -- In Fiscal 2017, Company Expects Mid-Single-Digit Revenue Growth, EPS Growth Roughly Double this Rate -Hologic, Inc. (Nasdaq: HOLX) has announced the Company's financial results for the fiscal... Read more

IMAGING Management

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2016 on November 2, 2016

2016 04 Oct

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2016 on Wednesday, November 2, 2016, after the market closes.  In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.Interested participants may listen to the call... Read more

IMAGING Management

Hologic Notice that Holders of 2% Convertible Exchange Senior Notes Due 2037 are Eligible to Convert

2016 04 Oct

Hologic, Inc. (Nasdaq: HOLX) has announced that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. 436440 AB7) issued November 23, 2010, and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes. This conversion right is subject to... Read more

IMAGING Management

Hologic CEO Steve MacMillan & Sheryl Crow Will Be Ringing the Nasdaq Opening Bell on October 3

2016 30 Sep

Hologic, Inc. (Nasdaq: HOLX) has announced that breast cancer survivor and Grammy Award-winner Sheryl Crow will join Steve MacMillan, the Company's Chairman, President and Chief Executive Officer, to ring the Nasdaq Opening Bell on October 3, in conjunction with the start of Breast Cancer Awareness Month.Hologic's participation in the bell ringing marks... Read more

IMAGING Management

FDA Expands Use Authorization for Hologic's Aptima® Zika Virus Assay to Use with Urine Sample

2016 09 Sep

Hologic, Inc. (Nasdaq: HOLX) has announced  that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for the company's Aptima® Zika virus diagnostic assay to be used with urine samples (collected alongside patient-matched serum or plasma specimens).Hologic's Zika virus assay was authorized for emergency use... Read more

IMAGING Management

NCCN Includes Breast Tomosynthesis in Breast Cancer Screening & Diagnosis Practice Guidelines

2016 01 Aug

Hologic Applauds NCCN for Recognizing the Comprehensive Body of Literature Supporting the Use of 3D MAMMOGRAPHY™ Exams for Breast Cancer ScreeningHologic Inc. (Nasdaq: HOLX) has announced that new guidelines published by the National Comprehensive Cancer Network (NCCN) recommend that physicians consider breast tomosynthesis exams as an option for their... Read more

IMAGING Management

Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037

2016 05 Jul

Hologic, Inc. (Nasdaq: HOLX) has announced that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. 436440 AB7) issued November 23, 2010, and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes.  This conversion right is subject... Read more

IMAGING Management

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2016 on July 27, 2016

2016 01 Jul

Hologic, Inc. (Nasdaq: HOLX) has announced that the Company plans to release its financial results for the third quarter of fiscal 2016 on Wednesday, July 27, 2016, after the market closes.  In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.Interested participants may listen to the call by dialing... Read more

Executive Health Management

FDA Approves Use of the Procleix Zika Virus Assay from Hologic & Grifols

2016 21 Jun

--Blood banks will use the new test, co-developed by Hologic and Grifols, to screen donated blood in potential endemic areas of the US----Test will run on the Procleix Panther System, a fully automated NAT blood screening platform--Hologic, Inc. (NASDAQ: HOLX) and Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) – market-leading partners committed to... Read more

IMAGING Management

FDA Grants Emergency Use Authorization for Hologic's Aptima® Zika Virus Assay

2016 20 Jun

New Diagnostic Test for the Detection of the Zika Virus Now Available for Use on Fully Automated Panther SystemHologic, Inc. (Nasdaq: HOLX) has announced that the U.S. Food and Drug Administration (FDA) granted emergency use authorization for the company's new, diagnostic assay for Zika virus infection. The Aptima® Zika Virus assay is a molecular diagnostic... Read more

IMAGING Management

KLAS Report Shows Hologic Continuing to Lead the U.S. Breast Tomosynthesis Market

2016 15 Jun

Mammography customers highlight Hologic's high image quality, strong customer support, and market-leading product innovationsHologic (NASDAQ: HOLX) has announced that the Company received top marks from U.S. mammography providers in a new independent report from KLAS Research, with 96 percent of customers reporting that Hologic systems are worth the... Read more

IMAGING Management

Sheryl Crow is Hologic's National Celebrity Spokesperson for New Breast Cancer Educational Campaign

2016 02 Jun

Award-winning performer and breast cancer survivor to educate women about early detection and the Genius™ 3D MAMMOGRAPHY™ examHologic, Inc. (NASDAQ: HOLX) has announced that nine-time Grammy award-winning singer, songwriter and breast cancer survivor Sheryl Crow will serve as national spokesperson to educate women about a more accurate mammogram, the... Read more

IMAGING Management

Hologic MyoSure® REACH Device Help Physicians Access the Upper Third of the Uterine Cavity

2016 11 May

Company Also Will Feature Full Range of Women's Health Topics at 2016 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific MeetingHologic, Inc. (Nasdaq: HOLX) has announced that the MyoSure® suite of gynecologic surgical products is expanding to include the MyoSure REACH device. The MyoSure REACH device confronts... Read more

IMAGING Management

Study Supports Screening with Pap+HPV Together™ as Best Way to Detect Cervical Cancer & Pre-Cancer

2016 03 May

Co-testing with Pap+HPV Together™ results in significantly fewer false-negative results than either test used alone 1A new cervical cancer screening study demonstrates that Pap+HPV Together™ (co-testing) remains the most effective strategy for detecting high-grade cervical lesions1,2, Hologic, Inc. (Nasdaq: HOLX) has announced. The study, published... Read more

IMAGING Management

Hologic Marks National Osteoporosis Month by Releasing New Consumer Survey

2016 02 May

New Data Suggests Nearly Half of Women Neglect to Take Action Against OsteoporosisWhile nearly three-quarters of Americans (71%) are aware of the effects that osteoporosis can have on their health, only about half report taking any steps to prevent it,1 according to the results of a new survey has announced by Hologic (Nasdaq: HOLX). To mark the start... Read more

IMAGING Management

Hologic Announces Financial Results for Second Quarter of Fiscal 2016

2016 28 Apr

- GAAP Diluted EPS of $0.24 Increases 41.2%, Non-GAAP Diluted EPS of $0.47 Increases 14.6% -- Revenue of $693.3 Million Grows 5.8% on a Reported Basis, 6.3% in Constant Currency -- Company Redeploys $460.2 Million of Capital to Reduce Convertible Debt, and Repurchase Shares -Hologic, Inc. (Nasdaq: HOLX) has announced the Company's financial results... Read more

IMAGING Management

JAMA Conclude that 3D MAMMOGRAPHY™ Exams Outperform Conventional Mammography

2016 27 Apr

Reducing Recall Rate for Breast Cancer Screening Stands to Decrease Healthcare Costs and Increase Quality of Care for WomenHologic, Inc. (Nasdaq: HOLX) has announced that study results published today in a research letter in JAMA conclude that breast tomosynthesis (Hologic's Genius™ 3D MAMMOGRAPHY™) exams reduce recall rates, and increase invasive cancer... Read more

IMAGING Management

Hologic Announces FDA Clearance and Commercial Availability of the Affirm™ Prone Biopsy System

2016 21 Apr

New System Pairs 360-Degree Breast Access with Exceptional 2D/3D™ Biopsy ImagingHologic, Inc. (Nasdaq: HOLX) has announced the U.S. Food and Drug Administration (FDA) clearance and commercial launch of the Affirm™ prone biopsy system, the first dedicated prone biopsy system to offer both 2D and 3D™ imaging-guided breast biopsies."At Hologic, we challenge... Read more

IMAGING Management

Hologic Symposium: High Volume Screening

2016 15 Feb

Several locations have started high volume screening with Hologic 3D Mammography™ in Europe. A large scale adoption is ongoing in the USA with some locations past their third screening round with Hologic 3D Mammography. Results from the use of this technology in screening are concordant and very positive around an increase in invasive cancer detection... Read more

IMAGING Management

Hologic 3D Mammography Workshop: Advanced Case Review

2016 15 Feb

Hologic is offering a series of 90-minute educational sessions for radiologists throughout the ECR Congress. Prior to the hands-on, a brief lecture will be provided by a radiologist pioneer in the clinical use of 3D Mammography™, who will present an overview of the technology and reading principles of tomosynthesis. This program is intended for radiologists... Read more

IMAGING Management

Hologic Innovation Workshop: Breast Biopsy

2016 15 Feb

Hologic is offering a series of 45-minute educational sessions for radiologists. A brief lecture will provide an overview of the clinical experiences with vacuum breast biopsies guided by 3D Imaging, prior to a demonstration of a phantom procedure using live imaging supervised by radiation protection services. This program is intended for radiologists... Read more

IMAGING Management

Hologic Innovation Workshop: Advanced Densitometry

2016 15 Feb

Hologic is offering a series of 45-minutes educational sessions for radiologists. A brief lecture will provide an overview of the clinical experiences of imaging and new quantification applications of DXA. This program is intended for radiologists interested in learning more about new application based on the Hologic DXA technology. Date WS n° Time 04/03/2016 HOL... Read more

IMAGING Management

Hologic Delivers Notice that Holders of 2.00% Converts Due 2037 are Eligible to Convert

2016 05 Jan

Hologic, Inc. (Nasdaq: HOLX) has announced that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. 436440 AB7) issued November 23, 2010, and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes.  This conversion right is subject... Read more

Jobs not available

Catalogue

    Catalogue not available

[email protected]
The Corporate Village, Building Caprese, 8th floor, Da Vincilaan 5
Zaventem
1935
Belgium
+32 2 711 46 80

White Papers - Case Studies

Not available

Videos

Articles

Not available